Kawasaki Disease - Diagnosis, IVIG, and Aspirin

Key Points

• Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
• Use system-specific risk tools to guide testing and disposition.
• Order high-yield tests first; escalate imaging when indicated.
• Start evidence-based initial therapy and reassess frequently.

Algorithm

1. Primary survey and vitals; IV access and monitors.
2. Focused history/physical; identify red flags and likely etiologies.
3. Order system-appropriate labs and imaging (see Investigations).
4. Initiate guideline-based empiric therapy (see Pharmacology).
5. Reassess response; arrange consultation and definitive management.

Clinical Synopsis & Reasoning

Approach AKI by distinguishing pre‑renal, intrinsic, and post‑renal causes. Trend creatinine and urine output, perform urinalysis with microscopy, and assess hemodynamics and exposures (nephrotoxins, contrast, ACEi/ARB, NSAIDs). Point‑of‑care ultrasound helps evaluate volume status and obstruction. Anticipate complications—hyperkalemia, acidosis, and fluid overload—that drive urgent interventions.

Treatment Strategy & Disposition

Optimize perfusion with judicious fluids when hypovolemic; discontinue nephrotoxins and adjust drug dosing. Treat hyperkalemia and severe acidosis promptly; initiate renal replacement therapy for AEIOU indications. Coordinate imaging with contrast only when benefits outweigh risks, using preventive strategies. Disposition depends on trajectory and complications—ICU for refractory electrolyte/volume issues or hemodynamic instability; otherwise monitored ward care.

Epidemiology / Risk Factors

• Risk factors vary by condition and patient profile

Investigations

Classic Clinical Features

Pharmacology

Prognosis / Complications

• Prognosis depends on severity, comorbidities, and timeliness of care

Patient Education / Counseling

• Explain red flags and when to seek emergent care.
• Reinforce medication adherence and follow-up plan.

Notes

Assess for sterile pyuria and elevated inflammatory markers. Counsel about live vaccines after IVIG.

References

1. AHA scientific statement on Kawasaki disease — Link
2. AAP Red Book and clinical reports — Link